Compare Cytokinetics Inc (CYTK) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs J M Smucker Co — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while J M Smucker Co trades at $119.43 (market cap $12.76B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.75% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and J M Smucker Co for 74 Days on average.
| CYTK | SJM | |
|---|---|---|
Market Cap | $8.62B | $12.76B |
Volume | 2,594,626 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $132.34 |
52-Week Low | $54.76 | $89.53 |
Typical Hold Time | 19 Days | 74 Days |
Enterprise Value | $8.72B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
SJM stock trades at $119.27, up 2.88% today, with a bullish technical signal from moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2025 results were impacted by a net loss of $1.23B. Analyst consensus is positive with a $138.23 price target, representing 16% upside potential. Recent news highlights strong execution and raised 2027 guidance, while technical indicators show support at $118 and resistance at $120.
The outlook remains cautiously optimistic with earnings momentum and raised guidance supporting upside, but investors face risks from volatile profitability, high debt levels, and competitive pressures in consumer staples. The stock offers value with reasonable P/S and EV/EBITDA multiples, though the elevated P/E ratio requires sustained earnings improvement to justify current valuation levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
